{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Désoxyribose : Questions médicales les plus fréquentes",
"headline": "Désoxyribose : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Désoxyribose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-15",
"dateModified": "2025-03-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Désoxyribose"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Désoses",
"url": "https://questionsmedicales.fr/mesh/D003837",
"about": {
"@type": "MedicalCondition",
"name": "Désoses",
"code": {
"@type": "MedicalCode",
"code": "D003837",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D09.254"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Désoxyribose",
"alternateName": "Deoxyribose",
"code": {
"@type": "MedicalCode",
"code": "D003855",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Zhiqiang Xie",
"url": "https://questionsmedicales.fr/author/Zhiqiang%20Xie",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Elemento-Organic Chemistry, Department of Chemical Biology, College of Chemistry, Nankai University, Tianjin 300071, China."
}
},
{
"@type": "Person",
"name": "Yuchen Yang",
"url": "https://questionsmedicales.fr/author/Yuchen%20Yang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Elemento-Organic Chemistry, Department of Chemical Biology, College of Chemistry, Nankai University, Tianjin 300071, China."
}
},
{
"@type": "Person",
"name": "Zhenghua Wang",
"url": "https://questionsmedicales.fr/author/Zhenghua%20Wang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Elemento-Organic Chemistry, Department of Chemical Biology, College of Chemistry, Nankai University, Tianjin 300071, China."
}
},
{
"@type": "Person",
"name": "Dejun Ma",
"url": "https://questionsmedicales.fr/author/Dejun%20Ma",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Elemento-Organic Chemistry, Department of Chemical Biology, College of Chemistry, Nankai University, Tianjin 300071, China."
}
},
{
"@type": "Person",
"name": "Zhen Xi",
"url": "https://questionsmedicales.fr/author/Zhen%20Xi",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Elemento-Organic Chemistry, Department of Chemical Biology, College of Chemistry, Nankai University, Tianjin 300071, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.",
"datePublished": "2023-03-04",
"url": "https://questionsmedicales.fr/article/36880088",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/jacamr/dlad011"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.",
"datePublished": "2022-08-18",
"url": "https://questionsmedicales.fr/article/36059480",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.901176"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36088952",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2352-4642(22)00245-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.",
"datePublished": "2023-10-19",
"url": "https://questionsmedicales.fr/article/37873026",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03085759231203019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.",
"datePublished": "2022-08-27",
"url": "https://questionsmedicales.fr/article/36145549",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/pharmaceutics14091801"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Glucides",
"item": "https://questionsmedicales.fr/mesh/D002241"
},
{
"@type": "ListItem",
"position": 3,
"name": "Désoses",
"item": "https://questionsmedicales.fr/mesh/D003837"
},
{
"@type": "ListItem",
"position": 4,
"name": "Désoxyribose",
"item": "https://questionsmedicales.fr/mesh/D003855"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Désoxyribose - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Désoxyribose",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Désoxyribose",
"description": "Comment le désoxyribose est-il détecté dans le corps ?\nQuels tests mesurent le désoxyribose ?\nLe désoxyribose est-il impliqué dans des maladies ?\nPeut-on mesurer le désoxyribose dans l'urine ?\nQuels sont les marqueurs associés au désoxyribose ?",
"url": "https://questionsmedicales.fr/mesh/D003855?mesh_terms=Probability&page=275#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Désoxyribose",
"description": "Quels symptômes sont liés à un déficit en désoxyribose ?\nLe désoxyribose affecte-t-il le métabolisme ?\nDes symptômes neurologiques peuvent-ils survenir ?\nLe désoxyribose est-il lié à des symptômes immunitaires ?\nQuels signes indiquent un problème avec le désoxyribose ?",
"url": "https://questionsmedicales.fr/mesh/D003855?mesh_terms=Probability&page=275#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Désoxyribose",
"description": "Comment prévenir les troubles liés au désoxyribose ?\nY a-t-il des mesures préventives spécifiques ?\nL'éducation nutritionnelle aide-t-elle ?\nLes dépistages sont-ils utiles ?\nLe mode de vie influence-t-il le désoxyribose ?",
"url": "https://questionsmedicales.fr/mesh/D003855?mesh_terms=Probability&page=275#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Désoxyribose",
"description": "Comment traiter un déficit en désoxyribose ?\nY a-t-il des médicaments pour le désoxyribose ?\nLe désoxyribose peut-il être administré par voie intraveineuse ?\nQuels sont les traitements alternatifs pour le désoxyribose ?\nLe désoxyribose peut-il être utilisé en thérapie génique ?",
"url": "https://questionsmedicales.fr/mesh/D003855?mesh_terms=Probability&page=275#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Désoxyribose",
"description": "Quelles complications peuvent survenir avec un déficit en désoxyribose ?\nLe désoxyribose est-il lié à des cancers ?\nDes problèmes cardiovasculaires peuvent-ils être liés ?\nLe désoxyribose affecte-t-il la fertilité ?\nQuelles sont les conséquences neurologiques possibles ?",
"url": "https://questionsmedicales.fr/mesh/D003855?mesh_terms=Probability&page=275#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Désoxyribose",
"description": "Quels facteurs augmentent le risque de troubles liés au désoxyribose ?\nL'âge influence-t-il le risque ?\nLes maladies métaboliques sont-elles un facteur de risque ?\nLe mode de vie peut-il influencer le risque ?\nLes infections virales sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D003855?mesh_terms=Probability&page=275#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le désoxyribose est-il détecté dans le corps ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le désoxyribose est généralement mesuré par des tests biochimiques sur des échantillons de sang ou de tissus."
}
},
{
"@type": "Question",
"name": "Quels tests mesurent le désoxyribose ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et chromatographiques peuvent être utilisés pour quantifier le désoxyribose."
}
},
{
"@type": "Question",
"name": "Le désoxyribose est-il impliqué dans des maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans le métabolisme du désoxyribose peuvent être liées à certaines maladies génétiques."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer le désoxyribose dans l'urine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le désoxyribose peut être détecté dans l'urine, mais c'est moins courant que dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les marqueurs associés au désoxyribose ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs de l'ADN et des acides nucléiques sont souvent associés au désoxyribose."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à un déficit en désoxyribose ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un déficit en désoxyribose peut entraîner des troubles de la croissance et des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "Le désoxyribose affecte-t-il le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le désoxyribose est essentiel pour le métabolisme des acides nucléiques et l'énergie cellulaire."
}
},
{
"@type": "Question",
"name": "Des symptômes neurologiques peuvent-ils survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans le métabolisme du désoxyribose peuvent être associées à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Le désoxyribose est-il lié à des symptômes immunitaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des déséquilibres dans le désoxyribose peuvent affecter la réponse immunitaire, entraînant des symptômes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un problème avec le désoxyribose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de fatigue, de faiblesse et des anomalies de croissance peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés au désoxyribose ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un suivi médical régulier peuvent aider à prévenir ces troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent être recommandés pour les familles à risque de troubles liés au désoxyribose."
}
},
{
"@type": "Question",
"name": "L'éducation nutritionnelle aide-t-elle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation nutritionnelle peut sensibiliser aux besoins en désoxyribose et en acides nucléiques."
}
},
{
"@type": "Question",
"name": "Les dépistages sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers peuvent aider à identifier précocement les troubles liés au désoxyribose."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le désoxyribose ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une bonne nutrition, peut influencer positivement le métabolisme du désoxyribose."
}
},
{
"@type": "Question",
"name": "Comment traiter un déficit en désoxyribose ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments de désoxyribose et une gestion des symptômes associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments pour le désoxyribose ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiques pour traiter les troubles liés au désoxyribose."
}
},
{
"@type": "Question",
"name": "Le désoxyribose peut-il être administré par voie intraveineuse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans certains cas cliniques, le désoxyribose peut être administré par voie intraveineuse."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements alternatifs pour le désoxyribose ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches nutritionnelles et des thérapies complémentaires peuvent être envisagées."
}
},
{
"@type": "Question",
"name": "Le désoxyribose peut-il être utilisé en thérapie génique ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent l'utilisation du désoxyribose dans des thérapies géniques pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec un déficit en désoxyribose ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des troubles métaboliques et des anomalies de croissance."
}
},
{
"@type": "Question",
"name": "Le désoxyribose est-il lié à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches suggèrent que des anomalies dans le métabolisme du désoxyribose pourraient être liées à certains cancers."
}
},
{
"@type": "Question",
"name": "Des problèmes cardiovasculaires peuvent-ils être liés ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres dans le désoxyribose peuvent contribuer à des problèmes cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Le désoxyribose affecte-t-il la fertilité ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans le métabolisme du désoxyribose peuvent potentiellement affecter la fertilité."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences neurologiques possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques peuvent survenir, notamment des troubles cognitifs et moteurs."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de troubles liés au désoxyribose ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de maladies génétiques et une mauvaise nutrition augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles liés au désoxyribose peuvent être plus fréquents chez les jeunes enfants."
}
},
{
"@type": "Question",
"name": "Les maladies métaboliques sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies métaboliques peuvent augmenter le risque de troubles liés au désoxyribose."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une alimentation déséquilibrée peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber le métabolisme du désoxyribose, augmentant le risque."
}
}
]
}
]
}
To assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-...
Adults with HABP/VABP were randomized 1:1 to IV imipenem/cilastatin/relebactam 1.25 g or piperacillin/tazobactam 4.5 g every 6 h for 7-14 days. Initial doses were selected by CL...
The modified ITT population comprised those with normal renal function (...
Prescribing information-defined dose adjustments in participants with baseline RI and full dosing of imipenem/cilastatin/relebactam 1.25 g every 6 h for participants with normal renal function or augm...
To identify less invasive and easily applicable serum cytokine-derived biomarkers which contribute to the diagnostic utility and risk assessment ability of the prostate health index (PHI) based multiv...
Serum 45 cytokines screening was performed in a small training cohort consisting of 10 sera by Luminex liquid array-based multiplexed immunoassays and identified TRAIL and IL-10 as new biomarkers for ...
TRAIL and IL-10 were identified as potential serum biomarkers for AG PCa detection by the result of multi-cytokines screening in the univariate analysis, while multivariable logistic regression confir...
We suggest a significant advantage for the PHI-based multivariate combinations of serum TRAIL and IL-10 comparing to PHI or other serum-derived biomarkers alone in the detection and risk stratificatio...
Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ...
In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig...
Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4...
An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass...
The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....
This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...
The World Health Organization recommends pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. The aim of this analysis is to quantify the individual risk of HIV infect...
The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi...
This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan....
In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ...
These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...
Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo...
Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander...
Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ...
This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba...
This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....
Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antena...
WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phospha...
This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmaco...
ISRCTN11434567 . Registered on 7 June 2021....